Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

MCRC × regorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 89 Carcinoma, Hepatocellular 23 Neoplasm Metastasis 18 Neoplasms 15 Gastrointestinal Stromal Tumors 12 Rectal Neoplasms 10 Colonic Neoplasms 10 Glioblastoma 7 Liver Neoplasms 6 Stomach Neoplasms 5 Sarcoma 5 Ovarian Neoplasms 5 Melanoma 5 Osteosarcoma 4 Carcinoma, Renal Cell 4 Carcinoma, Non-Small-Cell Lung 4 Adenocarcinoma 4 Small Cell Lung Carcinoma 3 Sarcoma, Ewing 3 Rhabdomyosarcoma 3 Pancreatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Esophageal Neoplasms 3 Colorectal Cancer Metastatic 3 Cholangiocarcinoma 3 Carcinoma, Transitional Cell 3 Carcinoma 3 Advanced Colorectal Cancer 3 Thyroid Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡